Study guide
11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia
Board Certified Pediatric Pharmacy Specialist BCPPS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure
1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation
2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles
2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development
3 Chapter 3: Neonatal Critical Care & Prematurity Complications
3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis
4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections
4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections
5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections
5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections
6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus
6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices
7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders
7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities
8 Chapter 8: Pediatric Cardiology & Hemodynamics
8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management
9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support
9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK
10 Chapter 10: Pediatric Neurology & Psychiatric Disorders
10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders
11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders
11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia
12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care
12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care
13 Chapter 13: Pediatric Medication Safety & Error Prevention
13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions
14 Chapter 14: Pediatric Compounding & Formulation Technology
14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities
15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support
15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation
16 Chapter 16: Pediatric Pain Management, Sedation & Delirium
16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies
17 Chapter 17: Biostatistics & Study Design in Pediatric Research
17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values
18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics
18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations
19 Chapter 19: Pediatric Education, Health Literacy & Communication
19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials
20 Chapter 20: Pediatric Immunizations & Public Health Advocacy
20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy
21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics
21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management
11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia
Key Takeaways Explain This Topic AI
Recombinant human growth hormone (somatropin) is dosed in mg/kg/week or mg/m2/week divided into daily evening subcutaneous injections: 0.16–0.24 mg/kg/week for growth hormone deficiency (GHD), and higher doses of 0.35–0.48 mg/kg/week for Turner syndrome, chronic kidney disease (CKD), and small for gestational age (SGA) failing catch-up growth by age 2 to 4 years.
Clinical monitoring for somatropin therapy mandates surveillance for slipped capital femoral epiphysis (SCFE presenting as hip/knee pain and limp), benign intracranial hypertension (pseudotumor cerebri with papilledema and headache), progression of scoliosis, and unmasking of central hypothyroidism.
Classic 21-hydroxylase deficiency (CYP21A2 mutation) causes >90-95% of congenital adrenal hyperplasia (CAH), producing 17-hydroxyprogesterone (17-OHP) accumulation, cortisol and aldosterone deficiency, and adrenal androgen excess, which triggers neonatal salt-wasting crisis (hyponatremia, hyperkalemia, shock, ambiguous genitalia in 46,XX females) between days 7 and 14 of life.
Maintenance pharmacotherapy for classic CAH requires short-acting oral hydrocortisone (8–15 mg/m2/day divided TID; avoiding long-acting dexamethasone/prednisone due to irreversible linear growth stunting), fludrocortisone (0.05–0.2 mg daily), and oral sodium chloride supplementation (1–2 g/day during infancy); physiological stress requires doubling or tripling oral hydrocortisone, or emergency parenteral Solu-Cortef (25–100 mg IV/IM).
Central Precocious Puberty (CPP; onset <8 years in girls, <9 years in boys) is managed with continuous GnRH receptor agonists (Leuprolide acetate depot IM, Triptorelin IM/SC, or the 12-month Histrelin subcutaneous implant) to desensitize pituitary receptors, suppress gonadotropins to prepubertal levels, arrest epiphyseal maturation, and preserve final adult height.
Last updated: September 2026
11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia
Pediatric endocrinology encompasses complex hormonal axes that govern linear growth, sexual maturation, and fluid-electrolyte homeostasis. Pharmacotherapy in these conditions requires precise developmental dosing calculations, careful mitigation of growth-stunting drug toxicities, and rapid emergency intervention during acute adrenal decompensation.
Recombinant Human Growth Hormone (Somatropin)
Somatropin is produced by recombinant DNA technology and has an identical 191-amino acid sequence to endogenous pituitary human growth hormone. It stimulates linear bone growth at the epiphyseal growth plates primarily through hepatic and peripheral production of Insulin-like Growth Factor 1 (IGF-1) , while exerting direct anabolic effects on skeletal muscle and lipolytic effects on adipose tissue. Somatropin Clinical Indications & Pediatric Dosing Spectrum:
- ┌─────────────────────────────┬───────────────────────────┬───────────────────────────────────────┐
- │ Pediatric Indication │ Dosing (mg/kg/week) │ Clinical Context & Monitoring Pearls │
- ├─────────────────────────────┼───────────────────────────┼───────────────────────────────────────┤
- │ Growth Hormone Deficiency │ 0.16 to 0.24 mg/kg/week │ Peak GH <10 ng/mL on 2 stim tests; │
- │ (GHD) │ (0.024–0.034 mg/kg/day) │ highly responsive to lower doses │
- ├─────────────────────────────┼───────────────────────────┼───────────────────────────────────────┤
- │ Turner Syndrome (45,XO) │ 0.35 to 0.375 mg/kg/week │ SHOX haploinsufficiency; relative GH │
- │ │ (up to 0.05 mg/kg/day) │ resistance; initiate at age 2–4 yr │
- ├─────────────────────────────┼───────────────────────────┼───────────────────────────────────────┤
- │ Small for Gestational Age │ 0.35 to 0.48 mg/kg/week │ Birth wt/length <-2 SD failing catch- │
- │ (SGA failing catch-up) │ (0.05–0.07 mg/kg/day) │ up growth by chronological age 2–4 yr │
- ├─────────────────────────────┼───────────────────────────┼───────────────────────────────────────┤
- │ Chronic Kidney Disease │ 0.35 mg/kg/week │ Uremic GH resistance; administer │
- │ (CKD prior to transplant) │ (~0.05 mg/kg/day) │ until renal transplantation occurs │
- ├─────────────────────────────┼───────────────────────────┼───────────────────────────────────────┤
- │ Prader-Willi Syndrome (PWS) │ 0.24 mg/kg/week │ Screen for sleep apnea/airway obstruc-│
- │ │ (or 1.0 mg/m2/day) │ tion before initiation (sudden death) │
- └─────────────────────────────┴───────────────────────────┴───────────────────────────────────────┘
- Administration & Therapeutic Drug Monitoring
Route & Timing: Administered via daily subcutaneous injections in the evening . Evening dosing mimics the natural physiological nocturnal secretion of growth hormone that occurs during slow-wave deep sleep.
Serum IGF-1 & IGFBP-3 Monitoring: Serum IGF-1 concentrations should be monitored every 6 to 12 months and maintained within the normal age- and sex-adjusted reference range ( -1 to +2 standard deviation scores [SDS] ). Elevated IGF-1 levels (> +2 SDS) mandate dose reduction to prevent acromegalic bone changes and metabolic complications.
Endocrine & Safety Labs:
Thyroid Function: Growth hormone accelerates the peripheral conversion of thyroxine (T4) to triiodothyronine (T3), which may unmask underlying central hypothyroidism . Free T4 and TSH should be checked at baseline and every 6 to 12 months.
Glucose Homeostasis: Somatropin antagonizes insulin signaling and stimulates hepatic gluconeogenesis; fasting glucose and HbA1c should be tracked in children with obesity or family risk of diabetes.
Adverse Effects & Critical Clinical Traps
Benign Intracranial Hypertension (Pseudotumor Cerebri): Typically presents within the first 8 to 12 weeks of initiation with severe morning headaches, nausea, vomiting, diplopia, and bilateral papilledema on fundoscopy. Somatropin must be discontinued immediately . Symptoms typically resolve within days to weeks; therapy may be cautiously re-introduced at a lower dose after complete ophthalmological resolution.
Slipped Capital Femoral Epiphysis (SCFE): Rapid linear growth places mechanical shear stress across the proximal femoral physis, causing posterior and medial displacement of the femoral head. Children present with hip, groin, or referred knee/thigh pain and an antalgic limp . Requires immediate non-weight bearing status and emergent orthopedic surgical evaluation for percutaneous in situ screw pinning.
Progression of Scoliosis: Rapid spinal growth can exacerbate preexisting scoliosis curves; spine surveillance is mandatory.
Prader-Willi Syndrome Airway Mortality: Recombinant GH can induce tonsillar hypertrophy and adenoidal enlargement. A formal polysomnography (sleep study) is mandatory prior to initiation to rule out severe upper airway obstruction; somatropin is contraindicated in severely obese PWS patients or those with severe respiratory impairment.
Congenital Adrenal Hyperplasia (CAH)
Congenital Adrenal Hyperplasia comprises a group of autosomal recessive disorders of adrenal steroidogenesis. Over 90% to 95% of cases are caused by mutations in the CYP21A2 gene encoding the 21-hydroxylase cytochrome P450 enzyme located on chromosome 6p21.3. Adrenal Steroidogenic Pathway in 21-Hydroxylase Deficiency (CAH):
- Cholesterol
- │
- ▼
- Pregnenolone ─────────────────► 17-OH Pregnenolone ────────► DHEA
- │ │ │
- ▼ ▼ ▼
- Progesterone ─────────────────► 17-OHP Androstenedione
- │ │ │
- 21-OHase ───X (BLOCKED!) 21-OHase ───X (BLOCKED!) ▼
- ▼ ▼ TESTOSTERONE
- 11-Deoxycorticosterone 11-Deoxycortisol │
- │ │ ▼
- ▼ ▼ VIRILIZATION IN UTERO
- ALDOSTERONE CORTISOL (Ambiguous Genitalia
- │ │ in 46,XX Females)
- ▼ ▼
- SALT-WASTING CRISIS LOSS OF NEGATIVE FEEDBACK
- (Hyponatremia, Shock, ON PITUITARY ──► MASSIVE
- Hyperkalemia) ACTH OVERPRODUCTION
- Pathophysiologic Consequences of 21-Hydroxylase Deficiency
Cortisol Deficiency & Pituitary Overactivation: Deficient cortisol synthesis eliminates normal negative feedback on the hypothalamus and anterior pituitary. The pituitary hypersecretes Adrenocorticotropic Hormone (ACTH) , which drives continuous hyperplasia of the adrenal cortex.
Steroid Precursor Accumulation & Androgen Shunting: The enzymatic block causes massive accumulation of upstream precursors, particularly 17-hydroxyprogesterone (17-OHP) and progesterone. These precursors are shunted into intact adrenal androgen synthesis pathways, generating massive excess of androstenedione and testosterone .
Aldosterone Deficiency: Complete or near-complete lack of 21-hydroxylase impairs mineralocorticoid production, causing renal sodium and water wasting, hypovolemia, and potassium retention.
Clinical Phenotypes & The Neonatal Salt-Wasting Crisis
Classic Salt-Wasting (SW) CAH (~75% of classic cases): Severe enzyme deficiency (<1% activity). Cortisol AND aldosterone are deficient.
In 46,XX Genetic Females: Exposed to massive androgen concentrations in utero, presenting at birth with ambiguous external genitalia (clitoral hypertrophy, labial fusion forming a scrotum-like structure, single urogenital sinus; Prader stages 1–5). Internal reproductive anatomy (uterus, fallopian tubes, ovaries) is completely normal.
In 46,XY Genetic Males: Genitalia appear normal at birth (sometimes subtle scrotal hyperpigmentation). Consequently, affected males escape neonatal visual detection and present between days 7 and 14 of life with life-threatening adrenal salt-wasting crisis .
Triad of Acute Salt-Wasting Crisis:
- Severe hyponatremia (serum Na < 120–125 mEq/L)
- Severe hyperkalemia (serum K > 7.0–8.5 mEq/L with peaked T waves and ventricular arrhythmias)
- Hypovolemic shock, dehydration (>10% weight loss from birth), and metabolic acidosis
- Frequent hypoglycemia (loss of cortisol counterregulation)
Clinical Trap: Frequently misdiagnosed as septic shock, pyloric stenosis, or congenital cardiac failure.
Diagnostic Confirmation: Newborn dried blood-spot screening demonstrates markedly elevated 17-hydroxyprogesterone (17-OHP) levels (often > 10,000 ng/dL vs. normal < 100–200 ng/dL), confirmed by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Pharmacotherapy of Classic CAH Pharmacotherapeutic Regimen for Classic Congenital Adrenal Hyperplasia:
1. GLUCOCORTICOID REPLACEMENT:
- Drug of Choice: ORAL HYDROCORTISONE (Cortisol)
- Dose: 8 to 15 mg/m2/day divided THREE TIMES DAILY (TID)
- Why Hydrocortisone? Short tissue half-life (1.5-2 hr) prevents irreversible growth stunting
- Avoid Dexamethasone & Prednisone in growing children! (Causes severe growth suppression)
- Monitoring: Titrated to normalize 17-OHP, androstenedione, and linear growth velocity
2. MINERALOCORTICOID REPLACEMENT:
- Drug: FLUDROCORTISONE ACETATE (Florinef)
- Dose: 0.05 to 0.2 mg orally once daily (or divided BID in neonates)
- Normalizes blood pressure, serum sodium, and suppresses plasma renin activity (PRA)
3. SODIUM CHLORIDE SUPPLEMENTATION (Infancy):
- Dose: Oral NaCl 1 to 2 g/day (~17 to 34 mEq/day) divided with breast milk / formula feedings
- Essential during first 12 months because infant diet has low sodium & infant kidneys resist aldosterone
4. STRESS-DOSING RULES (Illness / Surgery):
• Fever (>38.5°C) or moderate illness: DOUBLE or TRIPLE oral hydrocortisone (30-50 mg/m2/day)
- Emesis, shock, surgery, NPO: Emergency PARENTERAL SOLU-CORTEF IM/IV immediately:
- Age <3 years: 25 mg IM/IV bolus
- Age 3-12 years: 50 mg IM/IV bolus
- Age >12 years: 100 mg IM/IV bolus
- Why Hydrocortisone is the Exclusive Glucocorticoid of Choice
In pediatric patients with open epiphyses, oral hydrocortisone is the standard of care . It has low glucocorticoid potency (1.0 vs 4.0 for prednisone and 30.0 for dexamethasone) and a short biologic half-life (8 to 12 hours). This short duration minimizes nocturnal suppression of growth hormone release.
Prednisone and Dexamethasone Danger: Synthetic long-acting glucocorticoids have prolonged tissue residence times that cause profound hypothalamic-pituitary suppression, severe linear growth stunting, Cushingoid facies, truncal obesity, osteopenia, and significantly reduced adult height. They are strictly reserved for post-pubertal adolescents who have attained final adult height.
Stress-Dosing Protocols to Prevent Fatal Adrenal Crisis
During systemic illness, fever, or physical trauma, normal physiological cortisol production surges 3- to 5-fold. Children with CAH cannot mount this response:
Mild-to-Moderate Illness (Fever > 38.5°C, gastroenteritis without vomiting): Double or triple the baseline oral hydrocortisone dose ( 30 to 50 mg/m2/day divided TID or QID ). Fludrocortisone dosing remains unchanged.
Severe Stress, Persistent Emesis, Trauma, or General Anesthesia: Families and emergency personnel must immediately administer intramuscular Hydrocortisone sodium succinate (Solu-Cortef) at age-stratified doses (25 mg for <3 yr; 50 mg for 3–12 yr; 100 mg for ≥12 yr) and initiate emergency transport. Intravenous maintenance fluids containing 5% Dextrose in 0.9% Normal Saline (D5 0.9% NaCl) must be infused to correct hypoglycemia and hypovolemia.
Central Precocious Puberty (CPP)
Central Precocious Puberty (CPP, gonadotropin-dependent precocious puberty) is caused by premature, early reactivation of the hypothalamic pulsatile gonadotropin-releasing hormone (GnRH) pulse generator .
Diagnostic Thresholds: Appearance of secondary sexual characteristics before age 8 years in girls (breast bud development [thelarche] or pubarche) and before age 9 years in boys (bilateral testicular enlargement ≥ 4 mL [measured via Prader orchidometer] or pubarche).
Consequences: Premature production of sex steroids (estradiol or testosterone) drives rapid somatic growth velocity accompanied by accelerated skeletal maturation. This causes premature epiphyseal plate fusion , resulting in severe reduction in final adult height (frequently < 5 feet tall), alongside significant psychosocial distress. Mechanism of GnRH Receptor Down-Regulation by GnRH Agonists in CPP:
- Physiological State: Pulsatile GnRH Secretion (Every 60-90 min)
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ Hypothalamus ──► Pulsatile GnRH ──► Pituitary GnRH Receptors ──► LH & FSH │
- │ (Promotes normal receptor recycling & continuous pubertal sex steroid surge)│
- └─────────────────────────────────────────────────────────────────────────────┘
- │
- ▼ Continuous Agonist Infusion
- Therapeutic State: Continuous GnRH Agonist Therapy (Leuprolide, Histrelin)
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ Initial Phase (Days 1–14): Transient "Flare" of LH, FSH, and Sex Steroids │
- │ │ │
- │ Chronic Phase (> 2–4 Weeks): RECEPTOR INTERNALIZATION & DESENSITIZATION │
- │ • Pituitary uncoupling of G-protein signaling │
- │ • Profound suppression of LH (< 0.3–0.5 IU/L) and FSH │
- │ • Estradiol (< 10 pg/mL) & Testosterone (< 30 ng/dL) drop to prepubertal │
- │ • Linear growth velocity normalizes (4–6 cm/yr); bone age maturation stops │
- │ • Preserves and optimizes final adult height │
- └─────────────────────────────────────────────────────────────────────────────┘
- Pharmacotherapy with GnRH Agonists
Agent & Formulation Route & Dosing Interval Clinical Administration & Monitoring Pearls
Leuprolide Acetate Depot ( Lupron Depot-Ped ) Intramuscular (IM) ; • Monthly: 7.5 mg (≤25 kg), 11.25 mg (25–37.5 kg), 15 mg (>37.5 kg) q4 weeks; • 3-Month: 11.25 mg or 30 mg q12 weeks; • 6-Month: 45 mg q24 weeks Formulated in biodegradable poly(lactic acid) microspheres. Rotate injection sites. Transient sterile abscess or injection site granuloma occurs in 2–5% of patients.
Triptorelin ( Trelstar / Fensolvi ) IM or SC ; • Trelstar: 3.75 mg IM every 28 days; • Fensolvi: 22.5 mg SC every 6 months Fensolvi uses an in situ polymeric gel depot injected subcutaneously, reducing intramuscular injection pain.
Histrelin Implant ( Supprelin LA ) Subdermal Implant ; • 50 mg implant inserted subdermally into inner upper arm Delivers continuous zero-order release of histrelin (50–65 mcg/day) for 12 full months . Eliminates repeated painful injections and guarantees adherence. Explanted and replaced annually until desired pubertal timing.
Monitoring & Discontinuation Criteria
Suppression Verification: Clinical efficacy is confirmed by measuring GnRH-stimulated peak LH levels (suppressed to < 0.3 to 0.5 IU/L ), prepubertal estradiol (< 10 pg/mL in girls), and prepubertal testosterone (< 30 ng/dL in boys).
Skeletal & Growth Surveillance: Height velocity should decelerate to normal prepubertal rates ( 4 to 6 cm/year ), and bone age progression should stabilize relative to chronological age on annual hand/wrist radiographs.
Discontinuation Timing: Therapy is electively discontinued when the child reaches the chronologically appropriate age for normal puberty (typically age 11 years in girls and age 12 years in boys , or when bone age reaches ~12 to 12.5 years in girls and 13 to 13.5 years in boys). Normal hypothalamic-pituitary-gonadal axis pulsatility resumes within 6 to 12 months after drug cessation, culminating in normal spontaneous puberty, menarche, and future reproductive fertility.